These cell lines were chosen based on their CIP2A and SET overexpression levels (Figure 1B) and because they represent aggressive breast cancer phenotypes (MDA-MB-231: triple negative; BT-474: HER-2). This evidence concerns the gene CIP2A and breast cancer.